FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985553828> ?p ?o ?g. }

• W1985553828 endingPage "312" @default.
• W1985553828 startingPage "308" @default.
• W1985553828 abstract "Denosumab, a fully human monoclonal antibody against RANK ligand, increased bone mineral density (BMD) and reduced fracture risk vs placebo in a phase 3 trial in men with prostate cancer on androgen deprivation therapy (ADT). The present analysis of this study evaluated BMD changes after 36 months in responder subgroups and in individual patients for three key skeletal sites (lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius. Men with nonmetastatic prostate cancer receiving ADT were treated with subcutaneous denosumab 60 mg (n=734) or placebo (n=734) every 6 months for up to 36 months in a phase 3, randomized, double-blind study. Patients were instructed to take supplemental calcium and vitamin D. For this BMD responder analysis, the primary outcome measure was the percentage change in BMD from baseline to month 36 at the LS, FN and TH as measured by dual-energy X-ray absorptiometry. BMD at the distal 1/3 radius at 36 months was measured in a substudy of 309 patients. At 36 months, significantly more patients in the denosumab arm had increases of >3% BMD from baseline at each site studied compared with placebo (LS, 78 vs 17%; FN, 48 vs 13%; TH, 48 vs 6%; distal 1/3 radius, 40 vs 7% (P<0.0001 for all)). BMD loss at the LS, FN and TH occurred in 1% of denosumab-treated patients vs 42% of placebo patients, and BMD gain at all three sites occurred in 69% of denosumab patients vs 8% of placebo patients. Lower baseline BMD was associated with higher-magnitude BMD responses to denosumab at the LS, FN and TH. In men with prostate cancer receiving ADT, significantly higher BMD response rates were observed with denosumab vs placebo. Patients with lower baseline T-scores benefited the most from denosumab treatment." @default.
• W1985553828 created "2016-06-24" @default.
• W1985553828 creator A5000419121 @default.
• W1985553828 creator A5017925159 @default.
• W1985553828 creator A5024372930 @default.
• W1985553828 creator A5024994311 @default.
• W1985553828 creator A5042317118 @default.
• W1985553828 creator A5044327379 @default.
• W1985553828 creator A5053749991 @default.
• W1985553828 creator A5055221176 @default.
• W1985553828 creator A5066966992 @default.
• W1985553828 creator A5082556049 @default.
• W1985553828 date "2012-05-29" @default.
• W1985553828 modified "2023-09-27" @default.
• W1985553828 title "Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer" @default.
• W1985553828 cites W1553629958 @default.
• W1985553828 cites W1992053982 @default.
• W1985553828 cites W1992912488 @default.
• W1985553828 cites W1997732940 @default.
• W1985553828 cites W2005383842 @default.
• W1985553828 cites W2023408071 @default.
• W1985553828 cites W2024266959 @default.
• W1985553828 cites W2026707626 @default.
• W1985553828 cites W2036125852 @default.
• W1985553828 cites W2045765808 @default.
• W1985553828 cites W2048299560 @default.
• W1985553828 cites W2051963354 @default.
• W1985553828 cites W2054801098 @default.
• W1985553828 cites W2056810908 @default.
• W1985553828 cites W2059670446 @default.
• W1985553828 cites W2061172474 @default.
• W1985553828 cites W2066722676 @default.
• W1985553828 cites W2068210634 @default.
• W1985553828 cites W2078863172 @default.
• W1985553828 cites W2152578289 @default.
• W1985553828 cites W2156938611 @default.
• W1985553828 cites W2171595133 @default.
• W1985553828 cites W2917270815 @default.
• W1985553828 cites W4293409513 @default.
• W1985553828 doi "https://doi.org/10.1038/pcan.2012.18" @default.
• W1985553828 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3671885" @default.
• W1985553828 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22641239" @default.
• W1985553828 hasPublicationYear "2012" @default.
• W1985553828 type Work @default.
• W1985553828 sameAs 1985553828 @default.
• W1985553828 citedByCount "16" @default.
• W1985553828 countsByYear W19855538282013 @default.
• W1985553828 countsByYear W19855538282014 @default.
• W1985553828 countsByYear W19855538282015 @default.
• W1985553828 countsByYear W19855538282017 @default.
• W1985553828 countsByYear W19855538282019 @default.
• W1985553828 countsByYear W19855538282020 @default.
• W1985553828 countsByYear W19855538282021 @default.
• W1985553828 countsByYear W19855538282022 @default.
• W1985553828 crossrefType "journal-article" @default.
• W1985553828 hasAuthorship W1985553828A5000419121 @default.
• W1985553828 hasAuthorship W1985553828A5017925159 @default.
• W1985553828 hasAuthorship W1985553828A5024372930 @default.
• W1985553828 hasAuthorship W1985553828A5024994311 @default.
• W1985553828 hasAuthorship W1985553828A5042317118 @default.
• W1985553828 hasAuthorship W1985553828A5044327379 @default.
• W1985553828 hasAuthorship W1985553828A5053749991 @default.
• W1985553828 hasAuthorship W1985553828A5055221176 @default.
• W1985553828 hasAuthorship W1985553828A5066966992 @default.
• W1985553828 hasAuthorship W1985553828A5082556049 @default.
• W1985553828 hasBestOaLocation W19855538282 @default.
• W1985553828 hasConcept C121608353 @default.
• W1985553828 hasConcept C126322002 @default.
• W1985553828 hasConcept C126894567 @default.
• W1985553828 hasConcept C142724271 @default.
• W1985553828 hasConcept C143998085 @default.
• W1985553828 hasConcept C204787440 @default.
• W1985553828 hasConcept C27081682 @default.
• W1985553828 hasConcept C2775854910 @default.
• W1985553828 hasConcept C2776286101 @default.
• W1985553828 hasConcept C2776541429 @default.
• W1985553828 hasConcept C2776886416 @default.
• W1985553828 hasConcept C2777899217 @default.
• W1985553828 hasConcept C2779329777 @default.
• W1985553828 hasConcept C2780192828 @default.
• W1985553828 hasConcept C71924100 @default.
• W1985553828 hasConceptScore W1985553828C121608353 @default.
• W1985553828 hasConceptScore W1985553828C126322002 @default.
• W1985553828 hasConceptScore W1985553828C126894567 @default.
• W1985553828 hasConceptScore W1985553828C142724271 @default.
• W1985553828 hasConceptScore W1985553828C143998085 @default.
• W1985553828 hasConceptScore W1985553828C204787440 @default.
• W1985553828 hasConceptScore W1985553828C27081682 @default.
• W1985553828 hasConceptScore W1985553828C2775854910 @default.
• W1985553828 hasConceptScore W1985553828C2776286101 @default.
• W1985553828 hasConceptScore W1985553828C2776541429 @default.
• W1985553828 hasConceptScore W1985553828C2776886416 @default.
• W1985553828 hasConceptScore W1985553828C2777899217 @default.
• W1985553828 hasConceptScore W1985553828C2779329777 @default.
• W1985553828 hasConceptScore W1985553828C2780192828 @default.
• W1985553828 hasConceptScore W1985553828C71924100 @default.
• W1985553828 hasIssue "3" @default.
• W1985553828 hasLocation W19855538281 @default.

• next